Bdpalbo 75mg Capsule

About

Bdpalbo is an oral cyclin-dependent kinase (CDK) 4 and 6 inhibitor, primarily indicated for the treatment of certain types of advanced or metastatic breast cancer. It works by selectively inhibiting CDK4 and CDK6, key enzymes that regulate cell cycle progression. By blocking these kinases, Bdpalbo prevents cancer cells from advancing from the G1 phase to the S phase of the cell cycle, thereby inhibiting tumor cell proliferation. This targeted mechanism of action helps to slow down cancer growth and progression, particularly in hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, often in combination with endocrine therapy.

The medication is absorbed orally and undergoes extensive metabolism, primarily via CYP3A enzymes, with excretion predominantly through feces. Due to its potent antiproliferative effects, careful monitoring of hematologic parameters, particularly neutrophil counts, is crucial throughout treatment to manage potential myelosuppression. Patients should be educated on potential side effects and the importance of adherence to the prescribed regimen to maximize therapeutic benefits and ensure safety.

Uses

• Treatment of HR+, HER2- advanced or metastatic breast cancer.
• Used in combination with an aromatase inhibitor as initial endocrine-based therapy.
• Used in combination with fulvestrant after disease progression on endocrine therapy.
• Inhibits tumor cell proliferation in specific breast cancer types.

Directions For Use

Take the capsule orally once daily with food for 21 consecutive days, followed by 7 days off, to complete a 28-day cycle.

Benefits

• Targets specific cancer cell pathways.
• Slows progression of advanced breast cancer.
• Improves progression-free survival.
• Effective in combination with endocrine therapy.
• Oral administration for patient convenience.
• Offers a targeted treatment option for HR+, HER2- breast cancer.

Side Effects

• Neutropenia (low white blood cell count)
• Leukopenia
• Fatigue
• Nausea
• Diarrhea
• Stomatitis (mouth sores)
• Hair thinning or loss
• Infections
• Anemia
• Thrombocytopenia (low platelet count)
• Abnormal liver function tests
• Pulmonary embolism

Safety Measures

• Alcohol - Alcohol consumption should be limited or avoided during Bdpalbo treatment, as it may exacerbate side effects or interact with the drug's metabolism, potentially increasing toxicity.
• Pregnancy - Bdpalbo can cause fetal harm. It is contraindicated during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 3 weeks after the last dose.
• Breastfeeding - It is unknown if Bdpalbo is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for 3 weeks after the last dose.
• Liver - Patients with moderate to severe hepatic impairment may require dose adjustments for Bdpalbo, as it is primarily metabolized by the liver. Close monitoring of liver function is advised.
• Kidney - Dose adjustments may be necessary for patients with severe renal impairment. Bdpalbo is minimally excreted renally, but caution and monitoring are still recommended.
• Lung - Interstitial lung disease (ILD) and pneumonitis have been reported with CDK4/6 inhibitors. Patients should be monitored for pulmonary symptoms, and treatment should be interrupted or discontinued if severe symptoms occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.